Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based...
Cue Biopharma Announces Strategic Prioritization Of Autoimmune Programs; Anticipates Annualized Capital And Workforce Requirements To Be Reduced By ~25%; Expects To Reduce Its FY25 Operating Expenses By ~25%, To A Projected Annual Cash Burn, Based Upon Current Assumptions, Of ~$30M
Cue Biopharma宣佈對自身免疫項目進行戰略優先排序；預計年化資本和勞動力需求將減少約25％；預計其25財年的運營支出將減少約25％，根據目前的假設，預計年度現金消耗約爲3000萬美元
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical data continues to mature
優先考慮自身免疫項目旨在關注短期和中期價值創造潛力，同時隨着有希望的臨床數據不斷成熟，保留腫瘤學項目
- Company anticipates annualized capital and workforce requirements to be reduced by approximately 25 percent
-公司預計，年化資本和勞動力需求將減少約25％
BOSTON, July 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today announced the strategic prioritization of its autoimmune programs and organizational restructuring to strengthen operational efficiencies while enabling its encouraging oncology survival data to continue to mature.
波士頓，2024年7月25日（GLOBE NEWSWIRE）——Cue Biopharma, Inc.（納斯達克股票代碼：CUE）是一家處於臨床階段的生物製藥公司，正在開發一種用於選擇性地參與和調節疾病特異性T細胞的新型治療生物製劑。該公司今天宣佈將自身免疫項目和組織重組列爲戰略重點，以提高運營效率，同時使其令人鼓舞的腫瘤存活數據持續成熟。